New opportunities of using an ischemic cascade blocker in the therapy of acute myocardial infarction

Authors

  • V.M. Zhebel National Pirogov Memorial Medical University, Vinnytsia, Ukraine
  • O.L. Strazhynska National Pirogov Memorial Medical University, Vinnytsia, Ukraine

DOI:

https://doi.org/10.22141/2224-0586.18.1.2022.1456

Keywords:

acute coronary syndrome, edaravone, antioxidant, anesthetic management, children, dentistry, airway patency, outpatient surgery, review

Abstract

Oxidative stress plays a special role in acute coronary syndrome (ACS), in particular, is a leading link in the pathogenesis of reperfusion myocardial damage. The products of free radical oxi­dation can trigger the death of cardiomyocytes and are responsible for 50 % of the final size of the necrosis area in ACS, the occurrence of reperfusion arrhythmia, systolic and microvascular dysfunction. Therefore, adequate antioxidant therapy aimed at elimina­ting reac­tive oxygen species, activating antioxidants, modulating the processes of immediate and delayed cell death should be an important component of the management of patients with ACS. Edaravone is the most promising antioxidant and an ischemic cascade blocker due to its pharmacokinetic and pharmacodynamic properties. According to several experimental and clinical studies, the use of edaravone in patients with ACS leads to a decrease in the free radicals on the background of activation of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, catalase, to preserve the normal architecture of mitochondria and other cellular structures, to inhibit the expression of various proteins involved in the activation of apoptosis, ferroptosis, and proinflammatory response. At the clinical level, edaravone helps to reduce the area of necrosis with a significant decrease of plasma levels of CPK-MV, prevents the development of arrhythmias and systolic dysfunction on the background of ischemia/reperfusion. According to randomized, placebo-controlled studies, the use of edaravone in patients with ACS before reperfusion in the first 6 hours after the onset of symptoms is effective in reducing infarct area and preventing reperfusion arrhythmias. Thus, edaravone is a powerful antioxidant and an ischemic cascade blocker with additional anti-apoptotic and anti-ferroptotic, antinecrotic, anti-inflammatory effects, stabilizes cardiomyocytes and endothelial cells, and its administration in acute coronary syndrome is a promi­sing strategy for the prevention of reperfusion injury, myocardial and vascular remodeling. Due to its multifaceted effects, edaravone may also be useful in other cardiovascular diseases.

Downloads

Download data is not yet available.

References

Palatkina LO, Korneeva ON, Drapkina OM. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Cardiovascular Therapy and Prevention. 2012;11(6):91-94. (in Russian). doi: 10.15829/1728-8800-2012-6-91-94.

Ali ZK, Baker DE. Formulary Drug Review: Edaravone. Hosp Pharm. 2017 Dec;52(11):732-736. doi: 10.1177/0018578717734877.

Bainey KR, Armstrong PW. Clinical perspectives on reperfusion injury in acute myocardial infarction. Am Heart J. 2014 May;167(5):637-45. doi: 10.1016/j.ahj.2014.01.015.

Casas AI, Nogales C, Mucke HAM, et al. On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacol Rev. 2020 Oct;72(4):801-828. doi: 10.1124/pr.120.019422.

Chen H, Chen Y, Wang X, Yang J, Huang C. Edaravone attenuates myocyte apoptosis through the JAK2/STAT3 pathway in acute myocardial infarction. Free Radic Res. 2020 May;54(5):351-359. doi: 10.1080/10715762.2020.1772469.

Cui YG, Lu XN. Edaravone on reperfusion injury of acute myocardial infarction. Journal of Clinical Medicine in Practice. 2011;3:71-73.

Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575.

Fukuda A, Okubo S, Tanabe Y, et al. Cardioprotective effect of edaravone against ischaemia-reperfusion injury in the rabbit heart before, during and after reperfusion treatment. J Int Med Res. 2006 Sep-Oct;34(5):475-84. doi: 10.1177/147323000603400504.

González-Montero J, Brito R, Gajardo AI, Rodrigo R. Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities. World J Cardiol. 2018 Sep 26;10(9):74-86. doi: 10.4330/wjc.v10.i9.74.

Hassan MQ, Akhtar MS, Akhtar M, Ali J, Haque SE, Najmi AK. Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. Redox Rep. 2015;20(6):275-81. doi: 10.1179/1351000215Y.0000000011.

Hassan MQ, Akhtar MS, Akhtar M, Ali J, Haque SE, Najmi AK. Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. Ther Adv Cardiovasc Dis. 2016 Aug;10(4):214-23. doi: 10.1177/1753944716630653.

Hassan MQ, Akhtar MS, Afzal O, et al. Edaravone and benidipine protect myocardial damage by regulating mitochondrial stress, apoptosis signalling and cardiac biomarkers against doxorubicin-induced cardiotoxicity. Clin Exp Hypertens. 2020 Jul 3;42(5):381-392. doi: 10.1080/10641963.2019.1676770.

Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):85-93. doi: 10.2174/157489006775244191.

Homma T, Kobayashi S, Sato H, Fujii J. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. Exp Cell Res. 2019 Nov 1;384(1):111592. doi: 10.1016/j.yexcr.2019.111592.

Hou H. Study on the Protective Effect of Edaravone on Myocardial Ischemia Reperfusion Injury. Advanced Emergency Medicine. 2013;2(1):10-12. doi: 10.18686/aem.v2i1.48.

Ikegami E, Fukazawa R, Kanbe M, et al. Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death. Circ J. 2007 Nov;71(11):1815-20. doi: 10.1253/circj.71.1815.

Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol. 2014 Jun 2;2:702-14. doi: 10.1016/j.redox.2014.05.006.

Kikuchi K, Tancharoen S, Takeshige N, et al. The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 2013 Jul 4;14(7):13909-30. doi: 10.3390/ijms140713909.

Kiyuna LA, Albuquerque RPE, Chen CH, Mochly-Rosen D, Ferreira JCB. Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities. Free Radic Biol Med. 2018 Dec;129:155-168. doi: 10.1016/j.freeradbiomed.2018.09.019.

Li Q, Qiu Z, Lu Y, et al. Edaravone protects primary-cultured rat cortical neurons from ketamine-induced apoptosis via reducing oxidative stress and activating PI3K/Akt signal pathway. Mol Cell Neurosci. 2019 Oct;100:103399. doi: 10.1016/j.mcn.2019.103399.

Mankar VH. Edaravone based antioxidants for cardioprotection and neuroprotection. Plant Archives. 2020;20(Suppl 2):3440-3445.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2.

Nakamura Y, Yamada Y, Shimomura H, et al. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. J Cardiol. 2009 Dec;54(3):416-24. doi: 10.1016/j.jjcc.2009.07.001.

Neri M, Riezzo I, Pascale N, Pomara C, Turillazzi E. Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators Inflamm. 2017;2017:7018393. doi: 10.1155/2017/7018393.

Onogi H, Minatoguchi S, Chen XH, et al. Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1035-41. doi: 10.1111/j.1440-1681.2006.04483.x.

Oyama J, Satoh S, Suematsu N, et al. Scavenging free radicals improves endothelial dysfunction in human coronary arteries in vivo. Heart Vessels. 2010 Sep;25(5):379-85. doi: 10.1007/s00380-009-1221-7.

Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal. 2011 Mar 1;14(5):833-50. doi: 10.1089/ars.2010.3245.

Community Health Plan of Washington. Pharmacogenetic Testing Clinical Coverage Criteria. 2020.

Xu T, Ding W, Ji X, et al. Oxidative Stress in Cell Death and Cardiovascular Diseases. Oxid Med Cell Longev. 2019 Nov 4;2019:9030563. doi: 10.1155/2019/9030563.

Tsujita K, Shimomura H, Kawano H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004 Aug 15;94(4):481-4. doi: 10.1016/j.amjcard.2004.05.007.

Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J. 2006 Jul;70(7):832-7. doi: 10.1253/circj.70.832.

Xiang M, Lu Y, Xin L, et al. Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments. Oxid Med Cell Longev. 2021 May 18;2021:6614009. doi: 10.1155/2021/6614009.

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13;357(11):1121-35. doi: 10.1056/NEJMra071667.

Zhang GM, Wang Y, Li XY, Xu L, Su SP, Sun YY. Postconditioning of lactic acid and edaravone reduces apoptosis of myocardiocytes through the p38/JNK pathway. Chinese Journal of Geriatric Heart Brain and Vessel Diseases. 2013;(7):753-757.

Zhang GM, Wang Y, Li XY, et al. [Pharmacological postconditioning with lactic acid and low dose edaravone could attenuate myocardial reperfusion injury through mitochondrial pathway]. Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Aug;41(8):647-53. Chinese.

Zhang GW, Gu TX, Sun XJ, et al. Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. J Thorac Cardiovasc Surg. 2016 Aug;152(2):570-82. doi: 10.1016/j.jtcvs.2016.02.071.

Zhang WW, Bai F, Wang J, et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. Drug Des Devel Ther. 2017 Oct 16;11:3019-3033. doi: 10.2147/DDDT.S144807.

Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease. Biomed Pharmacother. 2022 Jan;145:112423. doi: 10.1016/j.biopha.2021.112423.

Zhao X, Zhang E, Ren X, et al. Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway. Biol Res. 2020 Jul 3;53(1):28. doi: 10.1186/s40659-020-00297-0.

Zhao ZQ, Velez DA, Wang NP, et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis. 2001 Aug;6(4):279-90. doi: 10.1023/a:1011335525219.

Zheng C, Liu S, Geng P, et al. Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion: a meta analysis. Int J Clin Exp Med. 2015 Feb 15;8(2):2205-11.

Published

2022-03-26

How to Cite

Zhebel, V., & Strazhynska, O. (2022). New opportunities of using an ischemic cascade blocker in the therapy of acute myocardial infarction. EMERGENCY MEDICINE, 18(1), 35–41. https://doi.org/10.22141/2224-0586.18.1.2022.1456

Issue

Section

Scientific Review